newsfilter
← Latest News
PR Newswire·

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...